The recent manuscript by Marega et al. 1 entitled 'BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and chronic phase/blast crisis chronic myeloid leukemia patients', which reported the BCR expression during the different stages of maturation of human myeloid cells provides important insight into the nature of chronic myeloid leukemia, particularly the similarity of BCR and BCR-ABL differential expression patterns during myeloid maturation in healthy subjects and patients with chronic-phase chronic myeloid leukemia, respectively. We studied the expression of BCR transcripts in the murine hematopoiesis. Similar to Marega et al., we found that BCR is differentially expressed during murine hematopoietic maturation. Further, our findings begin to address one of the conundrums ensuing from the work by Dr Eaves and her team in which it was reported that BCR-ABL transduction of mouse bone marrow resulted in expansion of granulocytes, lymphocytes and erythrocyte. 2 In fact, we performed our quantitative BCR transcript expression analysis in detailed stages of the murine hematopoietic hierarchy by assessing RNA obtained from single-cell progenitors with known fate, a strategy that has been previously published. [3] [4] [5] [6] The different stages of murine hematopoiesis that were analyzed included the long-term repopulating hematopoietic stem cells (LTR-HSCs) ) and are able to repopulate the entire hematopoietic system for 3-12 months, 6 the multipotent B þ (which have clonal potential erythroid (E), megakaryocytic (Meg), macrophagic (Mac), neutrophilic (Neut), mastocytic (Mast) and B lymphocyte (B)), pentapotent (with the potential E, Meg, Mac, Neut and mastocytic), the tetrapotent (with the potential E, Meg, Mac and Neut), the bipotent (pE/pMeg and pNeut/pMac), the unipotent (burst-forming unit-erythroid, colonyforming unit-erythroid, pMeg, pMac and pNeut) progenitors and, finally, the terminally differentiated cells (E, Meg, Mac, Neut, mastocytic, B and T); the lineage potentials of the different cells sampled are summarized in Figure 1a . Complementary DNA was obtained from sorted cells (LTR-HSCs, ITR-HSCs, mature B and mature T) or pooled from single cells, differentiation potential of which was determined by the outcome of cultured sibling cells (the multipotent B þ , the pentapotent, the tetrapotent, the bipotent, the unipotent and the terminally differentiated cells). In addition, we also analyzed BCR gene transcript levels in HSCs that were harvested from normal marrow in G0 phase and after stimulation, with Kit ligand, Flt3 ligand and IL-11, in culture to undergo mitosis. Furthermore, we compared BCR expression in LTR-HSCs and ITR-HSCs at entry into cell cycle (G1 phase) and again at a point when half of the cells had undergone mitosis (M phase); the distinction between these two stages was done on the basis of morphological criteria.
Indeed, high BCR transcript levels were seen in LTR-HSCs and interestingly in the pE/Meg progenitors (BCR/glyceraldehyde-3-phosphate dehydrogenase of 0.008 and 0.0093, respectively) ( Figure  1a and b), intermediate levels were found in ITR-HSCs and pentapotent and pNeut/Mac cells (BCR/glyceraldehyde-3-phosphate dehydrogenase ratios of 0.0022, 0.001 and 0.002, respectively), whereas low levels were detected in pMeg, pMac, pNeut, Meg and Neut (0.000231, 0.000073, 0.000239, 0.000158 and 0.000169) (Figure 1a and b). Finally, BCR Expression was not detected in the multipotent B þ , tetrapotent, burst-forming unit-erythroid, colonyforming unit-erythroid and the terminally-differentiated cells (E, Mac, mastocytic, B and T) (Figure 1a and b) . We also analyzed BCR gene transcript levels in HSCs that were harvested from normal marrow in G0 phase and after stimulation, in culture to undergo mitosis. Interestingly, when BCR transcript levels were compared in LTR-HSCs and ITR-HSCs harvested from normal marrow in G0 phase and after stimulation to undergo mitosis, cycling LTR-HSCs and ITR-HSCs showed 7.6-and 4.3-fold increase, respectively, in BCR transcripts (Figure 1c) .
Although we used different methodology for defining the different stages of hematopoietic maturation, our results indicate that the expression of BCR during the different stages of murine hematopoiesis are consistent with the results reported by Marega et al.
Letters to the Editor in human hematopoiesis, suggesting that BCR expression pattern during hematopoietic differentiation is likely conserved among species. Also, in accordance with what Marega et al. found in human hematopoiesis, our results indicate that BCR is differentially and tightly regulated during murine hematopoietic maturation. Whether this regulation is achieved at the pretranscriptional (through DNA methylation 7, 8 or histone modification), transcriptional or posttranscriptional (by microRNA) level is still to be determined. Finally, our results may help understanding some aspects of this disease, particularly the absence of erythrocytosis, which is a key feature of mouse transduction models. In these models, in contrast to chronic-phase chronic myeloid leukemia, BCR-ABL is expressed indiscriminately in all cell stages and types, and results in the expansion of all hematopoietic lineages 2 as it lacks the stage-and lineage-specific regulation of BCR transcription noted by Marega et al. and ourselves.
Conflict of interest
The authors declare no conflict of interest. 
Letters to the Editor
An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling Myelodysplastic syndromes (MDSs) comprise a heterogeneous group of disorders characterized by ineffective hematopoiesis presenting with peripheral cytopenias together with hyperplastic bone marrow. In addition, MDS patients show an increased risk of progression toward acute myeloid leukemia (AML). Although the pathogenetic mechanisms underlying both MDS and de novo AML development have broadly been studied on a genetic level, the molecular factors that determine the progression from MDS to secondary AML (s-AML) are largely unknown. So far, blast counts and cytogenetic abnormalities are known as major determinants of the risk for AML transformation, 1 however, little is known about the molecular genetic events associated with MDS progression to s-AML. De novo AML is characterized by a block in differentiation as well as hyperproliferation and increased survival of a malignant clone, which is due to several genetic alterations. In comparison, the etiology of s-AML can also be regarded as a multistep process wherein similar genes might be involved. These include class I and class II mutations which are involved in signal transduction (for example, FLT3 and NRAS) and transcriptional regulation (for example, RUNX1 and MLL) as well as alterations in NPM1. Recent studies on MDS pathogenesis have reported on widespread regions of uniparental disomy (UPD) across the entire genome with frequent sites of UPD found on chromosomes 1, 4, 6, 7 and 11. 2, 3, 4 Thus UPD may participate in the malignant pathological process and possibly disease progression, as accompanying loss of heterozygosity (LOH) may result in the duplication of a mutant allele located within the affected region. Comparisons of paired patient samples at both the MDS and s-AML stage provide an excellent model for studying the underlying genetic events responsible for the progression from MDS to s-AML. In the present study, we analyzed a total of 38 patients at both states of disease (male/female: 25/13; median age at diagnosis 69.5; range 29.2-82.9), who were referred to the MLL Munich Leukemia Laboratory between August 2005 and August 2009 for diagnostic workup, focusing on cytogenetic anomalies as well as molecular mutations in genes NPM1, MLL, NRAS, RUNX1
and FLT3. Additionally, we performed genome-wide SNP microarray analyses in 34 out of 38 patients at both time points. Mononuclear cells from bone marrow or peripheral blood were used for all cytogenetic, molecular and SNP array experiments.
Diagnosis was performed according to standard WHO (World Health Organization) criteria. 5 Patients gave their informed written consent for this investigation and the study adheres to the rules of the local Internal Review Board and the tenets of the revised Helsinki protocol. At initial MDS diagnosis, patients were classified according to the following WHO categories: RARS (n ¼ 2), RCMD (n ¼ 3), RAEB-1 (n ¼ 11), RAEB-2 (n ¼ 9), MDS unclassifiable (n ¼ 8), CMML (n ¼ 3) and MDS/MPN overlap (n ¼ 2). Progression to s-AML was defined by blasts 420% in bone marrow or peripheral blood. Even though CMML is not classified as MDS according to the new WHO classification, this entity was still included because of the presence of myelodysplastic features and the rather high transformation rate to AML. 5 AML transformation occurred at a median time of 269 days (range 40-1044 days) following initial MDS diagnosis. The high number of RAEB-1 and RAEB-2 patients (20/38; 52.6%) in our cohort reflects the fact that more advanced stages of MDS are particularly prone to s-AML progression.
For detailed evaluation, patients were grouped into three categories: (1) cases with cytogenetic progression (n ¼ 9, 24%) (2) cases with molecular genetic progression (n ¼ 10; 26%) and (3) cases with cytogenetic and molecular genetic progression (n ¼ 4; 11%). In all, 15 patients (39%) showed neither a change in karyotype nor in the molecular marker profile of the analyzed genes. In the total cohort at MDS stage, patients either exhibited a normal karyotype (n ¼ 27; 71%) or showed a single cytogenetic abnormality (n ¼ 8, 21%). One patient had two alterations and two patients displayed a complex aberrant karyotype.
In the course of disease evolution, 9/38 patients (24%, unique patient numbers; UPNs 1-9) showed increased cytogenetic complexity with gains of 1-10 aberrations in comparison to MDS stage (median number of gained anomalies ¼ 1) (Table 1 , subgroup: cytogenetic progression). Three patients (UPNs 2, 4 and 5) acquired a trisomy 8 which was the only recurrent
